NO329981B1 - Anvendelse av ET-743 ved fremstilling av et medikament, samt synergistisk kombinasjon som omfatter ET-743 og et annet antitumorlegemiddel. - Google Patents
Anvendelse av ET-743 ved fremstilling av et medikament, samt synergistisk kombinasjon som omfatter ET-743 og et annet antitumorlegemiddel. Download PDFInfo
- Publication number
- NO329981B1 NO329981B1 NO20032027A NO20032027A NO329981B1 NO 329981 B1 NO329981 B1 NO 329981B1 NO 20032027 A NO20032027 A NO 20032027A NO 20032027 A NO20032027 A NO 20032027A NO 329981 B1 NO329981 B1 NO 329981B1
- Authority
- NO
- Norway
- Prior art keywords
- use according
- combination
- drug
- treatment
- combination therapy
- Prior art date
Links
- PKVRCIRHQMSYJX-AIFWHQITSA-N trabectedin Chemical compound C([C@@]1(C(OC2)=O)NCCC3=C1C=C(C(=C3)O)OC)S[C@@H]1C3=C(OC(C)=O)C(C)=C4OCOC4=C3[C@H]2N2[C@@H](O)[C@H](CC=3C4=C(O)C(OC)=C(C)C=3)N(C)[C@H]4[C@@H]21 PKVRCIRHQMSYJX-AIFWHQITSA-N 0.000 title claims description 170
- 229960000977 trabectedin Drugs 0.000 title claims description 166
- XXPXYPLPSDPERN-UHFFFAOYSA-N Ecteinascidin 743 Natural products COc1cc2C(NCCc2cc1O)C(=O)OCC3N4C(O)C5Cc6cc(C)c(OC)c(O)c6C(C4C(S)c7c(OC(=O)C)c(C)c8OCOc8c37)N5C XXPXYPLPSDPERN-UHFFFAOYSA-N 0.000 title claims description 162
- 239000003814 drug Substances 0.000 title claims description 44
- 239000002246 antineoplastic agent Substances 0.000 title claims description 15
- 229940041181 antineoplastic drug Drugs 0.000 title claims description 12
- 239000011885 synergistic combination Substances 0.000 title claims description 6
- 238000004519 manufacturing process Methods 0.000 title description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 87
- 229960004679 doxorubicin Drugs 0.000 claims description 44
- 229940079593 drug Drugs 0.000 claims description 42
- 206010028980 Neoplasm Diseases 0.000 claims description 29
- 229930012538 Paclitaxel Natural products 0.000 claims description 27
- 229960001592 paclitaxel Drugs 0.000 claims description 27
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 27
- 238000011282 treatment Methods 0.000 claims description 24
- FJHBVJOVLFPMQE-QFIPXVFZSA-N 7-Ethyl-10-Hydroxy-Camptothecin Chemical compound C1=C(O)C=C2C(CC)=C(CN3C(C4=C([C@@](C(=O)OC4)(O)CC)C=C33)=O)C3=NC2=C1 FJHBVJOVLFPMQE-QFIPXVFZSA-N 0.000 claims description 21
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims description 21
- 206010039491 Sarcoma Diseases 0.000 claims description 20
- 229960004316 cisplatin Drugs 0.000 claims description 20
- 238000002648 combination therapy Methods 0.000 claims description 11
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims description 11
- 229960005277 gemcitabine Drugs 0.000 claims description 11
- 238000002360 preparation method Methods 0.000 claims description 9
- NOYPYLRCIDNJJB-UHFFFAOYSA-N trimetrexate Chemical compound COC1=C(OC)C(OC)=CC(NCC=2C(=C3C(N)=NC(N)=NC3=CC=2)C)=C1 NOYPYLRCIDNJJB-UHFFFAOYSA-N 0.000 claims description 9
- 229960001099 trimetrexate Drugs 0.000 claims description 9
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 claims description 6
- 201000011510 cancer Diseases 0.000 claims description 6
- 229960003048 vinblastine Drugs 0.000 claims description 6
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 claims description 6
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims description 5
- 229960003957 dexamethasone Drugs 0.000 claims description 5
- 206010006187 Breast cancer Diseases 0.000 claims description 3
- 208000026310 Breast neoplasm Diseases 0.000 claims description 3
- 208000029742 colonic neoplasm Diseases 0.000 claims description 3
- 206010009944 Colon cancer Diseases 0.000 claims description 2
- 201000003741 Gastrointestinal carcinoma Diseases 0.000 claims description 2
- 238000005538 encapsulation Methods 0.000 claims description 2
- 239000002502 liposome Substances 0.000 claims description 2
- 239000002077 nanosphere Substances 0.000 claims description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 61
- 230000000694 effects Effects 0.000 description 26
- 230000002195 synergetic effect Effects 0.000 description 19
- FTICVONBLRGQJW-UHFFFAOYSA-N 3-BrB-PP1 Chemical compound C12=C(N)N=CN=C2N(C(C)(C)C)N=C1CC1=CC=CC(Br)=C1 FTICVONBLRGQJW-UHFFFAOYSA-N 0.000 description 17
- 230000000996 additive effect Effects 0.000 description 14
- 239000003795 chemical substances by application Substances 0.000 description 13
- 230000022534 cell killing Effects 0.000 description 12
- 210000004881 tumor cell Anatomy 0.000 description 11
- 230000001472 cytotoxic effect Effects 0.000 description 10
- ZNJRHEVYOYMEHR-UHFFFAOYSA-N 5-methyl-6-[(3,4,5-trimethoxyanilino)methyl]quinazoline-2,4-diamine;trihydrochloride Chemical compound Cl.Cl.Cl.COC1=C(OC)C(OC)=CC(NCC=2C(=C3C(N)=NC(N)=NC3=CC=2)C)=C1 ZNJRHEVYOYMEHR-UHFFFAOYSA-N 0.000 description 9
- 208000021712 Soft tissue sarcoma Diseases 0.000 description 9
- 239000000654 additive Substances 0.000 description 9
- 231100000433 cytotoxic Toxicity 0.000 description 9
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 9
- 241000700159 Rattus Species 0.000 description 8
- 230000000259 anti-tumor effect Effects 0.000 description 8
- 230000005764 inhibitory process Effects 0.000 description 8
- 201000008968 osteosarcoma Diseases 0.000 description 8
- 201000008808 Fibrosarcoma Diseases 0.000 description 7
- 102100021888 Helix-loop-helix protein 1 Human genes 0.000 description 7
- 101000897691 Homo sapiens Helix-loop-helix protein 1 Proteins 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 7
- 238000001727 in vivo Methods 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 206010033128 Ovarian cancer Diseases 0.000 description 6
- 230000008485 antagonism Effects 0.000 description 6
- 210000000481 breast Anatomy 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 230000003993 interaction Effects 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 230000008406 drug-drug interaction Effects 0.000 description 5
- 238000001802 infusion Methods 0.000 description 5
- 238000011835 investigation Methods 0.000 description 5
- 230000007246 mechanism Effects 0.000 description 5
- 230000001988 toxicity Effects 0.000 description 5
- 231100000419 toxicity Toxicity 0.000 description 5
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 4
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 4
- 206010019851 Hepatotoxicity Diseases 0.000 description 4
- 239000012829 chemotherapy agent Substances 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 231100000304 hepatotoxicity Toxicity 0.000 description 4
- 230000007686 hepatotoxicity Effects 0.000 description 4
- 229960003552 other antineoplastic agent in atc Drugs 0.000 description 4
- 230000004614 tumor growth Effects 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 208000005243 Chondrosarcoma Diseases 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 241001529936 Murinae Species 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 238000008050 Total Bilirubin Reagent Methods 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000003042 antagnostic effect Effects 0.000 description 3
- 210000001072 colon Anatomy 0.000 description 3
- 229940127089 cytotoxic agent Drugs 0.000 description 3
- 230000003013 cytotoxicity Effects 0.000 description 3
- 231100000135 cytotoxicity Toxicity 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000012510 hollow fiber Substances 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 230000002611 ovarian Effects 0.000 description 3
- 230000036470 plasma concentration Effects 0.000 description 3
- 238000011255 standard chemotherapy Methods 0.000 description 3
- 231100000338 sulforhodamine B assay Toxicity 0.000 description 3
- 238000003210 sulforhodamine B staining Methods 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 206010008635 Cholestasis Diseases 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 241000699660 Mus musculus Species 0.000 description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 210000000013 bile duct Anatomy 0.000 description 2
- 206010006007 bone sarcoma Diseases 0.000 description 2
- 201000008275 breast carcinoma Diseases 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 231100000359 cholestasis Toxicity 0.000 description 2
- 230000007870 cholestasis Effects 0.000 description 2
- 238000011278 co-treatment Methods 0.000 description 2
- 239000002254 cytotoxic agent Substances 0.000 description 2
- 231100000599 cytotoxic agent Toxicity 0.000 description 2
- 238000002784 cytotoxicity assay Methods 0.000 description 2
- 231100000263 cytotoxicity test Toxicity 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000000890 drug combination Substances 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 230000009036 growth inhibition Effects 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 230000007866 hepatic necrosis Effects 0.000 description 2
- 206010019692 hepatic necrosis Diseases 0.000 description 2
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 230000033607 mismatch repair Effects 0.000 description 2
- 238000011580 nude mouse model Methods 0.000 description 2
- 210000001672 ovary Anatomy 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- IOOMXAQUNPWDLL-UHFFFAOYSA-N 2-[6-(diethylamino)-3-(diethyliminiumyl)-3h-xanthen-9-yl]-5-sulfobenzene-1-sulfonate Chemical compound C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=C(S(O)(=O)=O)C=C1S([O-])(=O)=O IOOMXAQUNPWDLL-UHFFFAOYSA-N 0.000 description 1
- 101100468589 Arabidopsis thaliana RH30 gene Proteins 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 1
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 208000001382 Experimental Melanoma Diseases 0.000 description 1
- 206010061968 Gastric neoplasm Diseases 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 101150066553 MDR1 gene Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 241000251555 Tunicata Species 0.000 description 1
- 102000007537 Type II DNA Topoisomerases Human genes 0.000 description 1
- 108010046308 Type II DNA Topoisomerases Proteins 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 229940045799 anthracyclines and related substance Drugs 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229940127093 camptothecin Drugs 0.000 description 1
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical group C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 238000007398 colorimetric assay Methods 0.000 description 1
- 229940000425 combination drug Drugs 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000005786 degenerative changes Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 229960001101 ifosfamide Drugs 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 206010024627 liposarcoma Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 231100000682 maximum tolerated dose Toxicity 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 238000004264 monolayer culture Methods 0.000 description 1
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 210000003200 peritoneal cavity Anatomy 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 238000009521 phase II clinical trial Methods 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000037425 regulation of transcription Effects 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000009044 synergistic interaction Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 210000001944 turbinate Anatomy 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Compounds Of Unknown Constitution (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US24623300P | 2000-11-06 | 2000-11-06 | |
US24809500P | 2000-11-13 | 2000-11-13 | |
US34598201P | 2001-10-19 | 2001-10-19 | |
PCT/GB2001/004902 WO2002036135A2 (en) | 2000-11-06 | 2001-11-06 | Compositions for antitumour treatment containing ecteinascidin 743 |
Publications (3)
Publication Number | Publication Date |
---|---|
NO20032027D0 NO20032027D0 (no) | 2003-05-06 |
NO20032027L NO20032027L (no) | 2003-07-04 |
NO329981B1 true NO329981B1 (no) | 2011-01-31 |
Family
ID=27399908
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20032027A NO329981B1 (no) | 2000-11-06 | 2003-05-06 | Anvendelse av ET-743 ved fremstilling av et medikament, samt synergistisk kombinasjon som omfatter ET-743 og et annet antitumorlegemiddel. |
Country Status (25)
Country | Link |
---|---|
US (3) | US20040108086A1 (da) |
EP (1) | EP1365808B1 (da) |
JP (2) | JP4391083B2 (da) |
KR (1) | KR100718946B1 (da) |
CN (1) | CN100374162C (da) |
AT (1) | ATE495793T1 (da) |
AU (2) | AU2002212499B2 (da) |
BG (1) | BG107843A (da) |
BR (1) | BR0115162A (da) |
CA (1) | CA2428160C (da) |
CY (1) | CY1112361T1 (da) |
CZ (1) | CZ20031327A3 (da) |
DE (1) | DE60143911D1 (da) |
DK (1) | DK1365808T3 (da) |
EA (1) | EA005564B1 (da) |
HK (1) | HK1060067A1 (da) |
HU (1) | HUP0400648A3 (da) |
IL (1) | IL155781A0 (da) |
MX (1) | MXPA03003975A (da) |
NO (1) | NO329981B1 (da) |
NZ (1) | NZ525730A (da) |
PL (1) | PL361389A1 (da) |
PT (1) | PT1365808E (da) |
SK (1) | SK287901B6 (da) |
WO (1) | WO2002036135A2 (da) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MY164077A (en) | 1999-05-13 | 2017-11-30 | Pharma Mar Sa | Compositions and uses of et743 for treating cancer |
MXPA02011319A (es) * | 2000-05-15 | 2003-06-06 | Pharma Mar Sa | Analogos antitumorales de ecteinascidina 743. |
DK1365808T3 (da) * | 2000-11-06 | 2011-05-16 | Pharma Mar Sa | Sammensætninger til antitumorbehandling indeholdende ecteinascidin 743 |
GB0117402D0 (en) * | 2001-07-17 | 2001-09-05 | Pharma Mar Sa | New antitumoral derivatives of et-743 |
JP2005509650A (ja) * | 2001-10-19 | 2005-04-14 | ファルマ・マール・ソシエダード・アノニマ | 癌治療における抗腫瘍化合物の改良した使用 |
GB0202544D0 (en) * | 2002-02-04 | 2002-03-20 | Pharma Mar Sa | The synthesis of naturally occuring ecteinascidins and related compounds |
US20050043233A1 (en) * | 2003-04-29 | 2005-02-24 | Boehringer Ingelheim International Gmbh | Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis |
GB0312407D0 (en) * | 2003-05-29 | 2003-07-02 | Pharma Mar Sau | Treatment |
GB0324201D0 (en) * | 2003-10-15 | 2003-11-19 | Pharma Mar Sau | Improved antitumoral combinations |
WO2005049031A1 (en) * | 2003-11-13 | 2005-06-02 | Pharma Mar, S.A.U. | Combination |
GB0326486D0 (en) * | 2003-11-14 | 2003-12-17 | Pharma Mar Sau | Combination treatment |
EP1691809A1 (en) * | 2003-11-14 | 2006-08-23 | Pharma Mar, S.A. | Combination therapy comprising the use of et-743 and paclitaxel for treating cancer |
US20080293725A1 (en) * | 2004-07-09 | 2008-11-27 | Rafael Rosell Costa | Prognostic Molecular Markers |
EP1812114A2 (en) * | 2004-09-29 | 2007-08-01 | Pharma Mar S.A., Sociedad Unipersonal | Ecteinascidin compounds as anti-inflammatory agents |
RU2359700C2 (ru) * | 2004-10-26 | 2009-06-27 | Фарма Мар С.А., Сосьедад Униперсональ | Пегилированный липосомальный доксорубицин в комбинации с эктеинасцидином 743 (ecteinescidin 743) |
WO2006046079A1 (en) | 2004-10-29 | 2006-05-04 | Pharma Mar S.A., Sociedad Unipersonal | Formulations comprising ecteinascidin and a disaccharide |
GB0522082D0 (en) * | 2005-10-31 | 2005-12-07 | Pharma Mar Sa | Formulations |
CA2630900A1 (en) * | 2005-11-25 | 2007-05-31 | University Of Medicine And Dentistry Of New Jersey | Use of parp-1 inhibitors |
US20100267732A1 (en) * | 2007-10-19 | 2010-10-21 | Pharma Mar, S.A. | Prognostic Molecular Markers for ET-743 Treatment |
CA2995025C (en) * | 2010-11-12 | 2020-04-28 | Pharma Mar, S.A. | Combination therapy with an antitumor alkaloid |
GB201217439D0 (en) * | 2012-09-28 | 2012-11-14 | Topotarget As | Combination therapy |
WO2014165818A2 (en) | 2013-04-05 | 2014-10-09 | T Cell Therapeutics, Inc. | Compositions and methods for preventing and treating prostate cancer |
JOP20190254A1 (ar) | 2017-04-27 | 2019-10-27 | Pharma Mar Sa | مركبات مضادة للأورام |
US10537585B2 (en) | 2017-12-18 | 2020-01-21 | Dexcel Pharma Technologies Ltd. | Compositions comprising dexamethasone |
CN109276719A (zh) * | 2018-11-01 | 2019-01-29 | 中山万汉制药有限公司 | 含有奥利司他纳米粒与蛋白激酶抑制剂的组合物 |
Family Cites Families (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5089273A (en) * | 1986-06-09 | 1992-02-18 | Board Of Trustees Of The University Of Illinois | Ecteinascidins 729, 743, 745, 759A, 759B and 770 |
US5149804A (en) * | 1990-11-30 | 1992-09-22 | The Board Of Trustees Of The University Of Illinois | Ecteinascidins 736 and 722 |
US5256663A (en) * | 1986-06-09 | 1993-10-26 | The Board Of Trustees Of The University Of Illinois | Compositions comprising ecteinascidins and a method of treating herpes simplex virus infections therewith |
DE3635711A1 (de) * | 1986-10-21 | 1988-04-28 | Knoll Ag | 5-nitrobenzo(de)isochinolin-1,3-dione, ihre herstellung und verwendung |
FR2697752B1 (fr) * | 1992-11-10 | 1995-04-14 | Rhone Poulenc Rorer Sa | Compositions antitumorales contenant des dérivés du taxane. |
US5478932A (en) * | 1993-12-02 | 1995-12-26 | The Board Of Trustees Of The University Of Illinois | Ecteinascidins |
US20040059112A1 (en) * | 1994-02-18 | 2004-03-25 | Rinehart Kenneth L. | Ecteinascidins |
GB9508195D0 (en) * | 1995-04-20 | 1995-06-07 | Univ British Columbia | Novel biologically active compounds and compositions,their use and derivation |
US5721362A (en) * | 1996-09-18 | 1998-02-24 | President And Fellows Of Harvard College | Process for producing ecteinascidin compounds |
US5985876A (en) * | 1997-04-15 | 1999-11-16 | Univ Illinois | Nucleophile substituted ecteinascidins and N-oxide ecteinascidins |
JP4562815B2 (ja) * | 1997-05-21 | 2010-10-13 | ジェネンテック, インコーポレイテッド | トロンボポエチンの新規な投与 |
BR9909488B1 (pt) * | 1998-04-06 | 2011-02-08 | ecteinascidinas semi-sintéticas e composição farmacêutica. | |
ES2239442T3 (es) * | 1998-05-11 | 2005-09-16 | Pharma Mar, S.A. | Metabolitos de ecteinascidina 743. |
JP2000081438A (ja) * | 1998-06-25 | 2000-03-21 | Sekisui Chem Co Ltd | 被験者の癌化学療法による免疫機能低下の測定方法 |
US6124292A (en) * | 1998-09-30 | 2000-09-26 | President And Fellows Of Harvard College | Synthetic analogs of ecteinascidin-743 |
MY164077A (en) * | 1999-05-13 | 2017-11-30 | Pharma Mar Sa | Compositions and uses of et743 for treating cancer |
AR035842A1 (es) * | 1999-05-14 | 2004-07-21 | Pharma Mar Sa | Metodo de hemisintesis para la formacion de compuestos intermediarios y derivados y de estructuras relacionadas con la ecteinascidina y de tetrahidroisoquinolinfenoles y compuestos intermediarios de aplicacion en dicho metodo |
US7247892B2 (en) * | 2000-04-24 | 2007-07-24 | Taylor Geoff W | Imaging array utilizing thyristor-based pixel elements |
US7420051B2 (en) * | 2000-05-15 | 2008-09-02 | Pharma Mar, S.A. | Synthetic process for the manufacture of an ecteinaschidin compound |
MXPA02011319A (es) * | 2000-05-15 | 2003-06-06 | Pharma Mar Sa | Analogos antitumorales de ecteinascidina 743. |
WO2002014554A2 (en) * | 2000-08-11 | 2002-02-21 | City Of Hope | The anti-neoplastic agent et-743 inhibits trans activation by sxr |
DK1365808T3 (da) * | 2000-11-06 | 2011-05-16 | Pharma Mar Sa | Sammensætninger til antitumorbehandling indeholdende ecteinascidin 743 |
WO2002076459A1 (en) * | 2001-03-06 | 2002-10-03 | Bristol-Myers Squibb Company | Method and dosage form for treating tumors by the administration of tegafur, uracil, folinic acid, paclitaxel and carboplatin |
JP4391038B2 (ja) * | 2001-05-10 | 2009-12-24 | パナソニック株式会社 | 電気炊飯器 |
JP2005509650A (ja) * | 2001-10-19 | 2005-04-14 | ファルマ・マール・ソシエダード・アノニマ | 癌治療における抗腫瘍化合物の改良した使用 |
US20040019027A1 (en) * | 2002-04-12 | 2004-01-29 | Barry Forman | Method of treating cerebrotendinous xanthomatosis |
GB0312407D0 (en) * | 2003-05-29 | 2003-07-02 | Pharma Mar Sau | Treatment |
GB0324201D0 (en) * | 2003-10-15 | 2003-11-19 | Pharma Mar Sau | Improved antitumoral combinations |
WO2005049031A1 (en) * | 2003-11-13 | 2005-06-02 | Pharma Mar, S.A.U. | Combination |
EP1691809A1 (en) * | 2003-11-14 | 2006-08-23 | Pharma Mar, S.A. | Combination therapy comprising the use of et-743 and paclitaxel for treating cancer |
GB0326486D0 (en) * | 2003-11-14 | 2003-12-17 | Pharma Mar Sau | Combination treatment |
US20080293725A1 (en) * | 2004-07-09 | 2008-11-27 | Rafael Rosell Costa | Prognostic Molecular Markers |
EP1812114A2 (en) * | 2004-09-29 | 2007-08-01 | Pharma Mar S.A., Sociedad Unipersonal | Ecteinascidin compounds as anti-inflammatory agents |
RU2359700C2 (ru) * | 2004-10-26 | 2009-06-27 | Фарма Мар С.А., Сосьедад Униперсональ | Пегилированный липосомальный доксорубицин в комбинации с эктеинасцидином 743 (ecteinescidin 743) |
WO2006046079A1 (en) * | 2004-10-29 | 2006-05-04 | Pharma Mar S.A., Sociedad Unipersonal | Formulations comprising ecteinascidin and a disaccharide |
CA2630900A1 (en) * | 2005-11-25 | 2007-05-31 | University Of Medicine And Dentistry Of New Jersey | Use of parp-1 inhibitors |
WO2007134203A2 (en) * | 2006-05-12 | 2007-11-22 | Pharma Mar, S.A. | Anticancer treatments with a combination of docetaxel and ecteinascidin |
-
2001
- 2001-11-06 DK DK01980710.6T patent/DK1365808T3/da active
- 2001-11-06 WO PCT/GB2001/004902 patent/WO2002036135A2/en active IP Right Grant
- 2001-11-06 HU HU0400648A patent/HUP0400648A3/hu unknown
- 2001-11-06 CZ CZ20031327A patent/CZ20031327A3/cs unknown
- 2001-11-06 EA EA200300544A patent/EA005564B1/ru not_active IP Right Cessation
- 2001-11-06 PT PT01980710T patent/PT1365808E/pt unknown
- 2001-11-06 JP JP2002538946A patent/JP4391083B2/ja not_active Expired - Fee Related
- 2001-11-06 CN CNB018218032A patent/CN100374162C/zh not_active Expired - Fee Related
- 2001-11-06 CA CA002428160A patent/CA2428160C/en not_active Expired - Fee Related
- 2001-11-06 US US10/416,086 patent/US20040108086A1/en not_active Abandoned
- 2001-11-06 IL IL15578101A patent/IL155781A0/xx unknown
- 2001-11-06 MX MXPA03003975A patent/MXPA03003975A/es active IP Right Grant
- 2001-11-06 EP EP01980710A patent/EP1365808B1/en not_active Revoked
- 2001-11-06 SK SK549-2003A patent/SK287901B6/sk not_active IP Right Cessation
- 2001-11-06 NZ NZ525730A patent/NZ525730A/xx not_active IP Right Cessation
- 2001-11-06 AT AT01980710T patent/ATE495793T1/de active
- 2001-11-06 KR KR1020037006228A patent/KR100718946B1/ko not_active IP Right Cessation
- 2001-11-06 AU AU2002212499A patent/AU2002212499B2/en not_active Ceased
- 2001-11-06 AU AU1249902A patent/AU1249902A/xx active Pending
- 2001-11-06 BR BR0115162-2A patent/BR0115162A/pt not_active IP Right Cessation
- 2001-11-06 DE DE60143911T patent/DE60143911D1/de not_active Expired - Lifetime
- 2001-11-06 PL PL01361389A patent/PL361389A1/xx not_active Application Discontinuation
-
2003
- 2003-05-06 NO NO20032027A patent/NO329981B1/no not_active IP Right Cessation
- 2003-05-23 BG BG107843A patent/BG107843A/bg unknown
-
2004
- 2004-05-04 HK HK04103120.3A patent/HK1060067A1/xx not_active IP Right Cessation
-
2009
- 2009-02-27 JP JP2009046557A patent/JP2009114212A/ja active Pending
- 2009-09-02 US US12/552,347 patent/US20090324744A1/en not_active Abandoned
-
2011
- 2011-04-18 CY CY20111100397T patent/CY1112361T1/el unknown
- 2011-12-30 US US13/341,262 patent/US20120107417A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO329981B1 (no) | Anvendelse av ET-743 ved fremstilling av et medikament, samt synergistisk kombinasjon som omfatter ET-743 og et annet antitumorlegemiddel. | |
AU2002212499A1 (en) | Compositions for antitumour treatment containing ecteinascidin 743 | |
EP2154971B1 (en) | A synergistic pharmaceutical combination for the treatment of cancer | |
RU2429838C2 (ru) | Комбинированная химиотерапия | |
US8927530B2 (en) | Therapeutic combination comprising a PLK1 inhibitor and an antineoplastic agent | |
RU2391101C2 (ru) | Комбинированное применение эктеинасцидина-743 и содержащих платину противоопухолевых соединений | |
US20110015135A1 (en) | Antitumoral Treatments | |
US9119877B2 (en) | Therapeutic combination comprising a Cdc7 inhibitor and an anti-neoplastic agent | |
US20110070232A1 (en) | Combination Therapy with an Antitumor Alkaloid | |
MXPA05001430A (es) | Combinaciones terapeuticas de inhibidores de quinasa de erb b y terapias antineoplasicas. | |
ES2358787T3 (es) | Composiciones para tratamiento antitumoral que contienen ecteinascidina 743. | |
Muggia et al. | iManagement (chemotherapy/best supportive care) of advanced-stage non-small cell lung cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM1K | Lapsed by not paying the annual fees |